Journal of Oncology

Research Article

Comparison of Involved Field Radiotherapy versus Elective Nodal Irradiation in Stage IIIB/C Non-Small-Cell Lung Carcinoma Patients Treated with Concurrent Chemoradiotherapy: A Propensity Score Matching Study

Table 4

Results of univariate and multivariate analysis.


Characteristic	Patients (N)	Median OS (months)	Univariate value	Multivariate value	Median LRPFS (months)	Univariate value	Multivariate value	Median PFS (months)	Univariate value	Multivariate value

Age group
<70 years	586	25.8	0.33	—	16.3	0.26	—	12.8	0.19	—
≥70 years	60	22.5	0.33	—	14.1	0.26	—	10.9	0.19	—

Gender
Male	400	24.1	0.51	—	14.4	0.62	—	10.9	O.48	—
Female	246	25.5	0.51	—	15.9	0.62	—	12.6	O.48	—

KPS
90–100	461	27.9	0.002	0.004	17.6	0.001	0.001	12.8	0.0011	0.024
70–80	185	22.6	0.002	0.004	13.9	0.001	0.001	10.7	0.0011	0.024

Histology
AC	348	24.4	0.84	—	14.7	0.75	—	12.2	0.39	—
SCC	298	25.3	0.84	—	15.9	0.75	—	11.0	0.39	—

T-stage
1-2	289	39.3	<0.001	<0.001	17.3	<0.001	<0.001	12.8	<0.001	<0.001
3-4	357	22.2	<0.001	<0.001	13.1	<0.001	<0.001	10.6	<0.001	<0.001

N-stage
2	325	30.4	<0.001	<0.001	19.3	<0.001	<0.001	14.7	<0.001	<0.001
3	321	19.9	<0.001	<0.001	11.0	<0.001	<0.001	8.3	<0.001	<0.001

Stage
IIIB	385	33.4	<0.001	<0.001	19.1	<0.001	<0.001	15.4	<0.001	<0.001
IIIC	261	20.2	<0.001	<0.001	10.8	<0.001	<0.001	7.9	<0.001	<0.001

Chemotherapy cycles
2-3	529	26.8	<0.001	<0.001	17.3	<0.001	<0.001	12.8	<0.001	<0.001
1	117	20.2	<0.001	<0.001	11.4	<0.001	<0.001	9.3	<0.001	<0.001

RT group
ENI	323	25.2	0.69	—	15.3	0.49	—	11.7	0.57	—
IFRT	323	24.6	0.69	—	15.1	0.49	—	11.2	0.57	—

OS: overall survival; LRPFS: locoregional progression-free survival; PFS: progression-free survival; KPS: Karnofsky performance score; SCC: squamous cell cancer; AC: adenocarcinoma; T: tumor; N: node; RT: radiotherapy; ENI: elective nodal irradiation; IFRT: involved-field radiotherapy.